Cantor Fitzgerald reiterated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $65.00 target price on the stock. Separately, Lifesci Capital reiterated an outperform rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six […]
Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have updated their coverage on the […]
Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is […]
Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) shot up 4.4% on Monday . The company traded as high as $44.40 and last traded at $44.35. 51,324 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 549,051 shares. The stock had previously closed at $42.50. Analysts Set New […]
Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has received a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued a report on the stock in […]